Importance <p>Vestibular dysfunction causes vertigo, dizziness, and imbalance, impairing daily life and leading to substantial healthcare use. Precise prevalence and economic impact remain unclear. </p> Objective <p>To estimate the one-year prevalence and direct healthcare costs of vestibular disorders in France.</p> Design <p>A matched case-control study using the French national health data system covering over 67 million records in 2022. </p> Setting <p>Nationwide health insurance data including all public and private healthcare interactions. </p> Population <p>Adults aged ≥18 years diagnosed or treated for vestibular disease, matched 1:1 with controls by age, sex, comorbidities, region, and deprivation.</p> Exposure <p>Vestibular disorder diagnosis or treatment in 2022. </p> Outcome <p>Direct healthcare expenditures in 2022 and 2023. </p> Results <p>Vestibular disorders affected 2.5% of adults (1,279,966 cases). Cases incurred mean costs of €4,233 versus €3,719 in controls in 2023, with an excess of €657 million nationally. </p> Conclusions and relevance <p>Vestibular disorders are common and associated with significant excess healthcare costs. Standardizing diagnostic and therapeutic pathways may reduce expenditures and improve care quality.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Prevalence and direct costs of vestibular disease in France – matched case-control study results from the 2022 and 2023 french health data system

  • Eva Grill,
  • Vincent Darrouzet,
  • Xavier Dubernard,
  • Dimitri Parise,
  • Stéphane Sanchez,
  • Andreas Zwergal,
  • Christian Chabbert

摘要

Importance

Vestibular dysfunction causes vertigo, dizziness, and imbalance, impairing daily life and leading to substantial healthcare use. Precise prevalence and economic impact remain unclear.

Objective

To estimate the one-year prevalence and direct healthcare costs of vestibular disorders in France.

Design

A matched case-control study using the French national health data system covering over 67 million records in 2022.

Setting

Nationwide health insurance data including all public and private healthcare interactions.

Population

Adults aged ≥18 years diagnosed or treated for vestibular disease, matched 1:1 with controls by age, sex, comorbidities, region, and deprivation.

Exposure

Vestibular disorder diagnosis or treatment in 2022.

Outcome

Direct healthcare expenditures in 2022 and 2023.

Results

Vestibular disorders affected 2.5% of adults (1,279,966 cases). Cases incurred mean costs of €4,233 versus €3,719 in controls in 2023, with an excess of €657 million nationally.

Conclusions and relevance

Vestibular disorders are common and associated with significant excess healthcare costs. Standardizing diagnostic and therapeutic pathways may reduce expenditures and improve care quality.